Detail akcie Fluidigm online

Business Summary: Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Standard Biotools Inc revenues decreased 27% to $82.1M. Net loss applicable to common stockholders excluding extraordinary items decreased 42% to $75.4M. Revenues reflect Americas segment decrease of 38% to $35.5M, Europe & Middle East & Africa (EMEA) segment decrease of 23% to $29M. Lower net loss reflects Transaction and integration expenses decrease of 94% to $1.4M (expense).